Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Medicina Interna de Harrison. 18ª ed. Rio de Janeiro: McGraw-Hill, Artmed, 2013.

Brasil. Ministério da Saúde. DATASUS Tecnologia da Informação a Serviço do SUS. [acesso em: 27.05.2014]. Disponível em: www.datasus.gov.br.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Update in 2014. [acesso em: 06.05.2014]. Disponível em: http://www.goldcopd.org/.

Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respiratory Research 2010;11:79.

Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31(2):416-468.

British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 65 ed. London: BMJ Publishing Group, APS Publishing, 2013.

Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, et al. A randomised trial of fluticasone furoate/vilanterol(50/25μg; 100/25μg) on lung function in COPD. Respir Med 2013;107(4):560-569.

Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, et al. Fluticasone furoate/vilanterol (100/25; 200/25μg) improves lung function in COPD: A randomised trial. Respir Med 2013;107(4):550-559.